Focus Partners Advisor Solutions LLC Sells 1,669 Shares of Amgen Inc. $AMGN

Focus Partners Advisor Solutions LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 18.7% during the third quarter, HoldingsChannel.com reports. The firm owned 7,234 shares of the medical research company’s stock after selling 1,669 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Amgen were worth $2,083,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. West Family Investments Inc. increased its stake in Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the period. TAGStone Capital Inc. lifted its position in shares of Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after acquiring an additional 32 shares during the period. BBR Partners LLC grew its holdings in shares of Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after purchasing an additional 32 shares in the last quarter. JFS Wealth Advisors LLC increased its position in shares of Amgen by 3.2% in the third quarter. JFS Wealth Advisors LLC now owns 1,070 shares of the medical research company’s stock worth $302,000 after purchasing an additional 33 shares during the period. Finally, Wealth Quarterback LLC raised its stake in Amgen by 1.6% in the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 34 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of Amgen stock opened at $379.27 on Thursday. The company’s 50 day moving average price is $351.83 and its two-hundred day moving average price is $321.58. The firm has a market capitalization of $204.45 billion, a P/E ratio of 26.65, a P/E/G ratio of 3.74 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the business earned $5.31 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of analyst reports. Argus increased their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Finally, BMO Capital Markets raised their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $354.17.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board declared a $2.52 per‑share dividend for Q2 2026 — a cash return and yield support that tends to be received positively by income and value investors. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen advanced its blinatumomab franchise with a new Phase 3 subcutaneous trial — if successful, a subcutaneous formulation can broaden use, improve patient convenience, and extend commercial life. This is a clinically material development for future revenue potential. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Positive Sentiment: Stock reached an annual high within a Nasdaq‑100 rally — positive technical momentum and index strength can attract flows and lift shares. Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally
• Neutral Sentiment: Broader media and analyst coverage (Zacks, Yahoo Finance pieces) is raising investor attention but contains mainly summaries and guidance rechecks rather than new fundamental catalysts. Increased coverage can boost trading volume and visibility. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Industry and market reports (asthma market outlook, competitor regulatory moves) are circulating; these are background items to monitor for longer‑term impact but not immediate stock drivers. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Short‑interest entries in recent feeds report a “significant increase” but show zero shares/NaN figures — this appears to be a data error rather than a genuine surge in shorting. Until reliable short‑interest data is available, treat these reports cautiously. (Data entries from March 3–4 appear inconsistent.)

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.